Related Experiment Video

Updated: Jun 26, 2026

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer

Tsukasa Seya1, Misako Matsumoto

  • 1Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Japan. seya-tu@pop.med.hokudai.ac.jp

Cancer Immunology, Immunotherapy : CII
|February 3, 2009
PubMed

Insights

Double-stranded RNA (dsRNA) from viral infections matures dendritic cells (DCs). This review explores how dsRNA and Toll-like receptor 3 (TLR3) signaling can be harnessed to enhance anti-tumor immunity.

Area of Science:

  • Immunology
  • Virology
  • Oncology

Background:

  • RNA viruses produce double-stranded RNA (dsRNA), a trigger for mature dendritic cell (mDC) development.
  • Toll-like receptor 3 (TLR3) senses dsRNA, activating TICAM-1 (TRIF) signaling pathways.
  • TLR3-TICAM-1 signaling influences cytokine production, apoptosis, and autophagy in immune and tumor cells.

Purpose of the Study:

  • To review the role of dsRNA in mDC maturation and immune responses.
  • To explore the potential of dsRNA in modulating the tumor microenvironment.
  • To investigate dsRNA's capacity to enhance anti-tumor cellular effectors.

Main Methods:

  • Literature review focusing on dsRNA sensing and downstream signaling pathways.
  • Analysis of mDC maturation processes induced by dsRNA.
  • Examination of immune cell activation, including CD8+ CTL, NK cells, and various CD4+ T cell subsets.
  • Investigation of TLR3-TICAM-1 pathway involvement in immune and tumor cells.

Main Results:

  • dsRNA induces mDC maturation, leading to cross-priming and CD8+ CTL induction.
  • dsRNA promotes NK cell activation and proliferation of CD4+ T cells (Th1, Th2, Treg, Th17).
  • TLR3-TICAM-1 signaling is a key mediator of dsRNA-induced cellular responses.

Conclusions:

  • dsRNA plays a critical role in initiating adaptive immune responses via mDC maturation.
  • Targeting dsRNA-TLR3-TICAM-1 pathways offers a strategy to enhance anti-tumor immunity.
  • Modulating the inflammatory milieu with dsRNA could potentiate cellular effectors against tumors.

More Related Videos

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Antigen Processing Pathways01:31

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.